Dacryocystitis Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 4.20 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Dacryocystitis Market Analysis
The dacryocystitis market studied is anticipated to register a CAGR of nearly 4.2%, during the forecast period.
Certain factors that are driving the market growth include a rise in the prevalence of eye infections and increasing clinical research and subsequent new product launches.
Dacryoadenitis is an inflammation of the lacrimal gland. Infections are rare and may be acute or chronic. Patients with acute dacryoadenitis suffer from a tender area of erythema and swelling in the lateral part of the upper lid. It may lead to preseptal or orbital cellulitis or may suppurate into an abscess.
As per the study titled 'Fungal infections of the eye', fungal dacryocystitis accounts for approximately 5% of all acquired dacryocystitis and around 14% of cases of congenital dacryocystitis. Women are affected more frequently with all forms of dacryocystitis than men, probably because of anatomically narrower nasolacrimal ducts. It mostly affects individuals in their 50s or 60s.
Dacryocystitis Market Trends
This section covers the major market trends shaping the Dacryocystitis Market according to our research experts:
Acute Dacryocystitis Holds Significant Share in the Dacryocystitis Market
Dacryocystitis can be acute or chronic and congenital or acquired. Symptoms of acute dacryocystitis start suddenly and often include fever and pus from the eye. Bacterial infections are usually the cause of acute dacryocystitis, and antibiotic treatment usually resolves the infection within a few days. People with acute dacryocystitis often experience more severe symptoms than those with chronic dacryocystitis. However, in all age groups, acute dacryocystitis generally resolves quickly after taking oral antibiotics.
North America Dominates the Dacryocystitis Market
The United States has witnessed a considerable rise in the number of dacryocystitis patients. According to the 2019 study (Grant D Gilliland et al), in adults, females are afflicted more commonly by dacryocystitis. Most studies demonstrate that 70-83% of cases of dacryocystitis occur in females. Congenital dacryocystitis occurs with equal frequency in both sexes. Moreover, the ease in the US government's regulations and the availability of funds from various organizations, like the National Institute of Health, have provided the potential for researchers to invest more in drug discovery for the disease.
Dacryocystitis Industry Overview
The dacryocystitis market is competitive and consists of a few major players. Companies like Aurobindo Pharma, Bess Medizintechnik GmbH, FCI Ophthalmics, Glaxosmithkline PLC, Kaneka Corporation, Mylan NV, Nosch, Orex Pharma Pvt Ltd, and Pfizer Inc., hold the substantial share in the market.
Dacryocystitis Market Leaders
-
Pfizer Inc.
-
Aurobindo Pharma
-
Orex Pharma Pvt Ltd
-
Nosch
-
Mylan NV
*Disclaimer: Major Players sorted in no particular order
Dacryocystitis Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Deliverables
- 1.2 Study Assumptions
- 1.3 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Rise in Prevalence of Eye Infections
- 4.2.2 Increasing Clinical Research and Subsequent New Product Launches
-
4.3 Market Restraints
- 4.3.1 Less Patient Awareness Regarding Various Treatment Procedures
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
-
5.1 By Indication
- 5.1.1 Acute
- 5.1.2 Chronic
- 5.1.3 Other Indications
-
5.2 By Distribution Channel
- 5.2.1 Institutional Sales
- 5.2.2 Retail Sales
-
5.3 By Geography
- 5.3.1 North America
- 5.3.1.1 United States
- 5.3.1.2 Canada
- 5.3.1.3 Mexico
- 5.3.2 Europe
- 5.3.2.1 Germany
- 5.3.2.2 United Kingdom
- 5.3.2.3 France
- 5.3.2.4 Italy
- 5.3.2.5 Spain
- 5.3.2.6 Rest of Europe
- 5.3.3 Asia-Pacific
- 5.3.3.1 China
- 5.3.3.2 Japan
- 5.3.3.3 India
- 5.3.3.4 Australia
- 5.3.3.5 South Korea
- 5.3.3.6 Rest of Asia-Pacific
- 5.3.4 Middle-East and Africa
- 5.3.4.1 GCC
- 5.3.4.2 South Africa
- 5.3.4.3 Rest of Middle-East and Africa
- 5.3.5 South America
- 5.3.5.1 Brazil
- 5.3.5.2 Argentina
- 5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Aurobindo Pharma
- 6.1.2 Bess Medizintechnik GmbH
- 6.1.3 FCI Ophthalmics
- 6.1.4 Glaxosmithkline PLC
- 6.1.5 Kaneka Corporation
- 6.1.6 Mylan NV
- 6.1.7 Nosch
- 6.1.8 Orex Pharma Pvt Ltd
- 6.1.9 Pfizer Inc.
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityDacryocystitis Industry Segmentation
As per the scope of the report, dacryocystitis refers to an infection of the tear sac (lacrimal sac) in the inner corner of the eye. It causes pain, redness, and swelling over the inner aspect of the lower eyelid and epiphora.
| By Indication | Acute | |
| Chronic | ||
| Other Indications | ||
| By Distribution Channel | Institutional Sales | |
| Retail Sales | ||
| By Geography | North America | United States |
| Canada | ||
| Mexico | ||
| By Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| By Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| By Geography | Middle-East and Africa | GCC |
| South Africa | ||
| Rest of Middle-East and Africa | ||
| By Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
Dacryocystitis Market Research FAQs
What is the current Dacryocystitis Market size?
The Dacryocystitis Market is projected to register a CAGR of 4.20% during the forecast period (2024-2029)
Who are the key players in Dacryocystitis Market?
Pfizer Inc. , Aurobindo Pharma , Orex Pharma Pvt Ltd, Nosch and Mylan NV are the major companies operating in the Dacryocystitis Market.
Which is the fastest growing region in Dacryocystitis Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Dacryocystitis Market?
In 2024, the North America accounts for the largest market share in Dacryocystitis Market.
What years does this Dacryocystitis Market cover?
The report covers the Dacryocystitis Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Dacryocystitis Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Dacryocystitis Industry Report
Statistics for the 2024 Dacryocystitis market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Dacryocystitis analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
